Atorvia

Atorvia is pre-clinical stage biotech company developing treatments for organ failure by targeting the regulated cell death pathways that cause it. Starting with the kidney, a first-in-class therapeutic is in development to prevent kidney failure during cardiac surgery, a common and serious complication. There is currently no treatment available.